Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | terminated | N/A | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04682431 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors |
| terminated |
| Phase 1 |
| 127 |
| Ikena OncologyINDUSTRY |
| 1 |
| Mar 22, 2024 |
| clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa(P2RX7) | terminated | N/A | 50 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04812743 | Colorectal Health Research Champions | terminated | N/A | 91 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03806244 | Feasibility of Stereotactic Navigation in Laparoscopic Surgery for Colorectal Cancer(PELVINAV) | terminated | N/A | 12 | IHU StrasbourgOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT04097795 | Incremental Cost-Utility Study on Prehabilitation Among Older Patients With Colorectal Cancer Undergoing Surgery(PreColo CU) | terminated | — | 72 | Radboud University Medical CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT04623515 | Radiation Therapy on Pelvic Floor Disorders in Women(RadPFD) | terminated | — | 49 | Wake Forest University Health SciencesOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | terminated | Phase 2 | 13 | Karyopharm Therapeutics IncINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00006046 | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer | terminated | Phase 1 | 7 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01011478 | Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery | terminated | Phase 3 | 406 | NSABP Foundation IncNETWORK | 2 | Aug 16, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05107661 | Colorectal Screening Strategies in Underserved Populations | terminated | — | 62 | Virtua Health, Inc.OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00470353 | Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery | terminated | N/A | 8 | Roswell Park Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00601198 | A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer | terminated | Phase 2 | 4 | University of CincinnatiOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT01468623 | Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6(PROFUSE) | terminated | Phase 4 | 51 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer(GEN206) | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04139967 | Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer | terminated | N/A | 2 | University of RochesterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT00002525 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed | terminated | Phase 3 | 859 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT01160926 | Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial(DREAMtherapy) | terminated | Phase 1 | 31 | The Christie NHS Foundation TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04882423 | Vegetable Intake Effect on Heterocyclic Amine Metabolism | terminated | N/A | 25 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT01239095 | Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection | terminated | Phase 1 | 23 | Richard WhelanOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial | terminated | Phase 1 / Phase 2 | 10 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03791398 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC(379) | terminated | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials